Response to Du et al., &quot;Beyond gastrointestinal symptom burden: integrating fecal calprotectin into a multimodal safety strategy before initiating bimekizumab in hidradenitis suppurativa&quot;.

Bimzelx (bimekizumab-bkzx) - UCB

http://www.ncbi.nlm.nih.gov/pubmed/42575320

Christina Crater; Christopher J Sayed; Delphine Deherder; Emily G Summers; Hans Herfarth

Aug 11, 2026